DDIT4 and ovarian cancer: Our data from 229 clinical specimens showed that high cytoplasmic REDD1 expression was associated with partial or non-response to chemotherapy (P < 0.001) in patients with ovarian carcinoma, suggesting that REDD1 plays an important role in ovarian cancer chemoresistance.